NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Price, News & Analysis $0.67 +0.04 (+5.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.66 0.00 (-0.62%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Moleculin Biotech Stock (NASDAQ:MBRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Moleculin Biotech alerts:Sign Up Key Stats Today's Range$0.59▼$0.6950-Day Range$0.27▼$0.9552-Week Range$0.25▼$3.65Volume2.13 million shsAverage Volume10.38 million shsMarket Capitalization$20.09 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. Read More Moleculin Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreMBRX MarketRank™: Moleculin Biotech scored higher than 58% of companies evaluated by MarketBeat, and ranked 410th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMoleculin Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Moleculin Biotech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($7.98) to ($4.79) per share.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Moleculin Biotech's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.97% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently increased by 52.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.97% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently increased by 52.03%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.36 News SentimentMoleculin Biotech has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Moleculin Biotech this week, compared to 2 articles on an average week.Search Interest16 people have searched for MBRX on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.MarketBeat Follows9 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $350,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 15.52% of the stock of Moleculin Biotech is held by institutions.Read more about Moleculin Biotech's insider trading history. Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Stock News HeadlinesMoleculin Biotech Releases Corporate Presentation UpdateAugust 1 at 5:30 PM | tipranks.comMoleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 31 at 4:43 AM | finanznachrichten.deMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alternative Assets reveals 3 urgent moves to protect your portfolio, plus the #1 asset class thriving during crises (hint: it’s not stocks or bonds). | American Alternative (Ad)Moleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 30 at 8:35 AM | globenewswire.comMoleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comMoleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comMoleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic PartnershipsJuly 17, 2025 | globenewswire.comMoleculin Biotech enters $6.5 million at-the-market equity offering ...July 13, 2025 | investing.comSee More Headlines MBRX Stock Analysis - Frequently Asked Questions How have MBRX shares performed this year? Moleculin Biotech's stock was trading at $1.70 at the start of the year. Since then, MBRX stock has decreased by 60.9% and is now trading at $0.6651. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.02. Read the conference call transcript. When did Moleculin Biotech's stock split? Moleculin Biotech shares reverse split on Friday, March 22nd 2024.The 1-15 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moleculin Biotech investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings5/13/2025Today8/01/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MBRX CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Moleculin Biotech$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+501.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-278.80% Return on Assets-100.11% Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.77 per share Price / Book0.38Miscellaneous Outstanding Shares30,210,000Free Float29,573,000Market Cap$20.09 million OptionableNot Optionable Beta1.39 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:MBRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.